Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Jivi

    market access in Japan

    Implementation of Cost-Effectiveness Analysis in Japan’s Health Technology Assessment Process

    Japan’s evolving approach to market access includes a formal cost-effectiveness analysis (CEA) requirement for certain new medicines and medical devices. Introduced as part of a broader health technology assessment (HTA)...

    Petauri Evidence

    Bayer symbol

    Bayer’s Kerendia granted FDA approval for new heart failure indication

    Approximately 55% of the 6.7 million adults in the US with HF have an LVEF of at least 40%

    Bayer symbol

    Bayer’s Vitrakvi receives full FDA approval for NTRK gene fusion-positive tumours

    The US regulator first approved the TRK inhibitor in 2018 under its accelerated approval pathway

    - PMLiVE

    Sobi receives NICE recommendation for Altuvoct in severe haemophilia A

    Approximately 7,700 people in England are living with the genetic bleeding disorder

    - PMLiVE

    FDA grants RMAT designation to AskBio’s Parkinson’s gene therapy candidate

    The progressive neurodegenerative disease affects more than ten million people worldwide

    - PMLiVE

    Sobi receives MHRA approval for Altuvoct in severe or moderate haemophilia A

    The factor VIII replacement therapy has been authorised to treat and prevent bleeding in children and adults

    - PMLiVE

    Novo Nordisk’s haemophilia A therapy Mim8 shows promise in late-stage study

    The inherited bleeding disorder accounts for up to 85% of the 1,125,000 global haemophilia cases

    Bayer symbol

    Bayer UK launches digital educational hub to improve menopause support

    An estimated 13 million women in the UK are currently perimenopausal or menopausal

    Bayer symbol

    Bayer’s non-hormonal menopause drug shows promise in phase 3 breast cancer trial

    Breast cancer patients can experience vasomotor symptoms as a result of adjuvant endocrine therapy

    Bayer symbol

    Bayer presents positive results for Kerendia in late-stage heart failure study

    Approximately 55% of the 6.7 million heart failure patients in the US have an LVEF of at least 40%

    Bayer symbol

    Bayer and NextRNA Therapeutics enter oncology partnership worth $547m

    The companies will advance small molecule therapeutics against a new class of targets for cancer

    Bayer symbol

    Bayer shares promising results for Kerendia in phase 3 heart failure study

    Approximately 55% of heart failure patients have an LVEF of at least 40%

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links